Insulet Rolls Out Omnipod 5 Algorithm Upgrade with Libre 3 Plus Support

In early June 2026, Insulet Corporation (NASDAQ: PODD) began rolling out FDA-cleared algorithm enhancements to its Omnipod 5 Automated Insulin Delivery System in the U.S. The update adds a 100 mg/dL glucose target option and new compatibility with Abbott Laboratories' (NYSE: ABT) Libre 3 Plus sensor. The enhancements are delivered via over-the-air (OTA) updates and newly shipped Pods.

The Product

The update represents a significant step in diabetes management personalization, allowing users to select a tighter glucose target of 100 mg/dL, which may improve glycemic control. Compatibility with the Libre 3 Plus expands sensor choices, offering greater flexibility for patients and clinicians.

Pricing and Availability

Insulet has not announced any pricing changes related to the update. The update is available now for existing users via OTA and will be included in new Pod shipments.

Competition

The Omnipod 5 competes with systems like Medtronic 780G and Tandem Control-IQ. This update strengthens Omnipod 5's competitive position by offering broader customization and multi-sensor compatibility.

Potential Impact on Insulet

The update could drive increased adoption of Omnipod 5 among diabetes patients, boosting Insulet's revenue in the automated insulin delivery segment. The partnership with Abbott also reinforces Insulet's role in the diabetes management ecosystem.